Free Trial
→ Our $1 AI stock to buy right now (From Behind the Markets) (Ad)
NYSE:CYBN

Cybin 2/14/2024 Earnings Report

Cybin logo
$6.08 -0.42 (-6.46%)
Closing price 04:00 PM Eastern
Extended Trading
$6.20 +0.12 (+1.91%)
As of 06:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Earnings HistoryForecast

Cybin EPS Results

Actual EPS
-$0.07
Consensus EPS
-$0.03
Beat/Miss
Missed by -$0.04
One Year Ago EPS
N/A

Cybin Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cybin Announcement Details

Quarter
Date
2/14/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Cybin Earnings Headlines

Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003
April 23, 2025 | businesswire.com
Cybin initiated with a Buy at Guggenheim
March 12, 2025 | markets.businessinsider.com
Elon’s Terrifying Warning Forces Trump To Take Action
Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of collapse and built two of the most valuable companies in history. Now, he's sounding the alarm about America's $36 trillion debt time bomb that could destroy the fabric of our society.As head of the Department of Government Efficiency (DOGE) under President Trump, Musk is exposing just how bad things are...
May 6, 2025 | American Hartford Gold (Ad)
Analysts Offer Insights on Healthcare Companies: Cybin (CYBN) and Corbus Pharmaceuticals (CRBP)
February 18, 2025 | markets.businessinsider.com
Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights
February 10, 2025 | businesswire.com
Cybin’s depression program advancing in Phase 3, says H.C. Wainwright
January 28, 2025 | markets.businessinsider.com
See More Cybin Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cybin? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cybin and other key companies, straight to your email.

About Cybin

Cybin (NYSE:CYBN), a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.

View Cybin Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles